Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$25.8M Sell
201,087
-100
-0% -$11.7K 0.56% 37
2026
Q1
$24.2M Sell
201,187
-5,661
-3% -$654K 0.6% 37
2025
Q4
$21.8M Buy
206,848
+5,577
+3% +$524K 0.54% 37
2025
Q3
$16.9M Buy
201,271
+2,649
+1% +$218K 0.44% 50
2025
Q2
$15.7M Sell
198,622
-605
-0.3% -$48.1K 0.44% 54
2025
Q1
$17.9M Buy
199,227
+20,302
+11% +$1.9M 0.57% 41
2024
Q4
$17.8M Buy
+178,925
New +$18.4M 0.58% 41

Other funds holding MRK

Cary Street Partners's MRK Position: Q2 2026 in Review

Cary Street Partners reduced its Merck (MRK) stake by 0.05% in Q2 2026, selling an estimated $11.7K and leaving 201,087 shares worth $25.8M. The position accounts for 0.56% of the portfolio, ranked #37.

Cary Street Partners first reported a position in MRK in Q4 2024 and has held it in 7 quarters since. 1,533 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Cary Street Partners held 201,087 shares of Merck worth $25.8M as of Q2 2026.
  • Cary Street Partners sold 100 Merck shares in Q2 2026, an estimated $11.7K.
  • Merck made up 0.56% of Cary Street Partners's portfolio in Q2 2026, its #37 holding.
  • Cary Street Partners first reported a position in Merck in Q4 2024 and has held it in 7 quarters since.
  • 1,533 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.